Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 103, Issue 17, 2011, Pages 1299-1309

  Amir, E ^a   Seruga, Bostjan ^a,b   Niraula, Saroj ^a   Carlsson, Lindsay ^c   Ocaña, Alberto ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; TAMOXIFEN CITRATE;

BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ENDOMETRIUM CARCINOMA; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECOND CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAMOXIFEN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 80052663463     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr242     Document Type: Review

References (33)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431-2442.
2. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(suppl 7):vii10-vii14.
3. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486-492.
4. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484
5. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
6. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
7. Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol. 2009;27(6):840-842.
8. Hughes-Davies L, Caldas C, Wishart GC. Tamoxifen: the drug that came in from the cold. Br J Cancer. 2009;101(6):875-878.
9. Seruga B, Ocana A, Niraula S, Amir E. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28(20):e346-347.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
11. Deeks JJ, Higgins JPT, Altman DG, eds. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4 2 5. In: The Cochrane Library; Chichester, UK: John Wiley & Sons, Ltd; 2006.
12. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323(7305):157-162.
13. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559- 570.
14. Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010;121(2):379-387.
15. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321-331.
16. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol. 2009;62(6):609-616.
17. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112(2):260-267.
18. Food and Drug Administration. Anastrozole: Full Prescribing Information.http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020541s024s025lbl.pdf. Accessed November 11, 2010.
19. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001;98(6):3589-3593.
20. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36):5715- 5722.
21. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115(11):860-864.
22. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80(11):3191-3195.
23. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993;85(17):1398-1406.
24. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995;311(7011):977-980.
25. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271.
26. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965-1971.
27. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845-1853.
28. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86(20):1534-1539.
29. Landi G, D'Angelo A, Boccardi E, et al. Hypercoagulability in acute stroke: prognostic significance. Neurology. 1987;37(10):1667-1671.
30. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke. 1990;21(8):1111-1121.
31. Ring A, Sestak I, Baum M, et al. The influences of co-morbidities and age on risk of death without recurrence: a retrospective analysis of the ATAC trial. Cancer Res. 2010;70(24 suppl):403s-404s.
32. Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102(13):942-949.
33. Liauw WS, Day RO. Adverse event reporting in clinical trials: room for improvement. Med J Aust. 2003;179(8):426-428.